Apples are the most commonly found fruit in the market and the best part is that they are available right through the year. Along with vitamins and minerals, apples have phytonutrients that are quite beneficial for health.
Both of the above properties lead to a reduced intake of calories and a long term weight loss. The health benefits of apples have been studied in depth because of the popularity of the fruit. Studies hint that eating apples can help lower the levels of blood sugar and protects against diabetes. The antioxidants present in apples slow down the digestion of sugars, slowing down their absorption. Studies have been conducted to see the effect of apples on cholesterol levels and they have been positive too but only on lab animals. Filed Under: Food, Health, health benefits, Nutrition and Diet, Nutrition Facts, Weight Loss, Weight Loss Blog Tagged With: cancer, health benefits, heart health, nutrition facts, type 2 diabetes, weight loss, Why Apples Are Good For Weight Loss And Health? Here on fitnessvsweightloss we write about fitness, weight loss,mobile app reviews,weight loss product reviews,Fitness studio review, dieticians etc.
You can also see why RS is hard to get in any meaningful amount eating a typical paleo or SAD diet. I found that when I ran out of potato starch and switched over to plantain starch, above average fartage for a day or so, then back to normal.
Even beans not properly prepared by soaking don’t give me much in the way of farts, anymore. A lot of explanation have already been done, for example, on Hyperlipid blog, Vilhjalmur Stefansson and his former expedition member had more elevated FBS on their all-meat diet(while feeling more healthy) . It looks like physiological IR is the way a body saves glucose for where it is needed absolutely.
Every VLC person on earth has retained water, gained weight (oh, myyyy), had localized inflammation (this was plain fucking stupid–if you had local inflammation on a tooth, this was to fight an infection, dumbass), and been in the doldrums.
Wolfstriked: as far as I understand it, the fact that method A – In vivo (ileostomy or intubation in living human) measured the RS means that the percentage is after the food has already been in the body for hours. My question would be: if I can saute my potatoes in the evening, and let them sit in the fridge overnight to increase their RS, can I then re-heat them without reducing the RS level to what they were before cooling? The deal with heating and cooling is a chemical process called retrogradation–the gelled starch crystallizes as it cools forming a type of resistant starch. It would be really difficult to accurately predict your RS intake using the list I provided because there are so many variables. Hey Janet, I planned to take some handfuls of Fritos corn chips and just re fry them in extra virgin olive oil. I don’t mind my anecdotal n=1 to be dismissed, but mostly I wanted to point out that some explanations you requested were given by less dismissable people.
Galina, even if for some reason you can’t tolerate normal starch at all, you realise there is a difference between that and starch YOU don’t primarily digest, that is instead primarily digested by bacteria in your gut, right?
Beans are against my religion ?? I feel better keeping it nutrient dense and not so much volume.
This whole RS road-show is more about getting the info out about RS, what it does and where it’s found than to convince every single reader that they absolutely must eat more RS or else. The people I feel who should take steps to really try to get more are those who have been following SAD, paleo, or any other diet plan that completely eliminates all sources of RS and most fiber.
Brad, I tried RS only in the form of cooled cooked potatoes(not green bananas or powdered potato starch), often in the form of a salad – mix of cooked potatoes, cooked beets , raw onions, homemade pickles or sauerkraut, typical for my native cuisine . Cooked, cooled potatoes, etc., is a MIXTURE of mostly regular, rapidly-digested starch plus resistant starch. To revise my above analogy, it’s the difference between Metamucil powder and brownies with added fiber. It’s pretty damn exacting science to me, unless you want $2000 worth of corals to crash.
I went through many, many iterations with the latest tequniques, because the original way to keep a reef tank was simply 80% water changes every week to dilute the nitrates.
On September 12, Sanofi announced that it withdrew the FDA application for its once-daily GLP-1 agonist lixisenatide (named Lyxumia in Europe) for type 2 diabetes. The FDA was originally expected to rule on Lyxumia by the end of 2013 with interim data from ELIXA (mid-term data collected while the trial is still running).
Sanofi emphasized that the withdrawal was not related to safety issues or to problems with the drug application — rather, it worried that the FDA’s review process might jeopardize the integrity of the ELIXA trial if the interim data were released.
For more information on Lyxumia and GLP-1 agonists, please read our new now next in diaTribe #52. On February 1, the European Commission announced that it had approved Sanofi and Zealand Pharma’s GLP-1 agonist Lyxumia (lixisenatide) for type 2 diabetes. Sanofi has submitted a new drug application for lixisenatide in the US (the trade name has not been determined in the US yet), and on February 19 the FDA accepted the application.
With many GLP-1 agonists available, patients and their HCPs will need to decide which of these will serve them best.
As such, following these results, Amylin Pharmaceuticals and Eli Lilly, the maker of Byetta, filed an application with the FDA in late December 2010 asking the agency to approve the use of Byetta as an add-on to basal insulin therapy for type 2 patients.
GLP-1 agonists (for example, Byetta, Victoza, and Bydureon) were first approved in 2005 and stimulate the body to produce insulin only when blood glucose levels become too high.
The second piece of news this month came from GlaxoSmithKline, which announced positive clinical trial results for its new once-weekly GLP-1 agonist (albiglutide) when used in combination with basal insulin therapy. Finally, even further down the road, we also heard an update from Sanofi and Zealand Pharma on their novel pen device that will allow users to inject both Lyxumia (the companies’ once-daily GLP-1 agonist) and Lantus at the same time, eliminating one extra shot per day.

Our mission is to help individuals better understand their diabetes and to make our readers happier & healthier. Our mission is to help individuals better understand their diabetes and to make our readers happier and healthier. On a study conducted on women, it was found that eating an apple a day, reduced the risk of type 2 diabetes by 28%!!
Studies have been carried out on lab animals and they have confirmed that the phytonutrients in apple protect against lung and colon cancer. And it was alarming because I had no knowledge of PIR at the time and often experienced high FBG readings myself. If anyone has questions about how the food was prepared or where the values came from, they can easily go to the paper I got the info from.
The essential dietary requirement for resistant starch to feed gut bacteria and its universal benefits is well established over 30 years, in hundreds of studies. Some days it’s a heaping T or two, other days none, and other days just a t, and at different times.
I had my last potato chip on January 3, 2003 because I just could not eat one bag, let alone 1 chip.
At least it would have only good oil on them and if the salt is only on the surface and it is removed by the re frying, I can just sprinkle salt on them. SSs as were talked about were basically rice & potatoes, mostly rapidly digesting starch. I believe that thus far, oly a single person has made a cautionary argument about RS based on actual science and not complete confusion and ignorance.
I don’t doubt that part of population could be fine eating starches, the thing I doubt is the totally negative perseption of physiological IR.
A 180 gal big fish tank with too high of nitrates to keep invertebrates who can barely stand a measurable level but fish can take up to about 40 ppm. But low and behold, after many gizmos and many, many methods we came upon a simple solution: 6-8 inches on sand in the bottom.
The drug was withdrawn to allow Lyxumia’s cardiovascular outcomes trial ELIXA to run to completion before a final FDA ruling. Trial data released to the public could affect how health care providers and participants in the study behave during the rest of the study and bias the final results.
LixiLan (an exciting combination of lixisenatide and the basal insulin Lantus) is still on schedule to begin phase 3 testing in the first half of 2014.
The drug is a once-daily injection that is particularly useful for controlling after-meal blood glucose levels – early trial results suggested it may be even better than Novo Nordisk’s Victoza specifically for post-meal spikes, but perhaps not in other areas of glucose control.
If approved by the FDA, lixisenatide will become the fourth GLP-1 agonist available on the market, following Victoza, Byetta, and Bydureon. Usually, the FDA takes around 10 months to review such applications, placing possible approval in October 2011.
Novo Nordisk is conducting clinical trials for its GLP-1 agonist Victoza in combination with its long-acting analog insulin Levemir, and plans to begin trials later this year to combine Victoza and Degludec, the company’s ultra-long acting insulin that is now in phase 3 trials. Lately, the concept of using a GLP-1 agonist with a basal insulin (such as Levemir and Lantus) has received more attention; the use of this combination to treat type 2 diabetes offers a number of advantages. The first announcement was that the GLP-1 agonist Victoza was finally approved for use with any basal insulin in the US.
In the trial, 500 people with type 2 diabetes received either a weekly injection of albiglutide in combination with a daily injection of Lantus or a daily injection of Lantus in combination with mealtime injections of the prandial insulin Humalog. Notably, the companies announced that their pen device will allow users to adjust their Lantus dose while receiving the same dose of Lyxumia every time.
Humans who ate 1 or more apples a day were found to be at a lower risk of getting cancer of the breast and colon. Her dad has been type II for over 40 years, so it’s a good precaution for her to take. I plan to make a blend of potato starch, plantain flour and tapioca starch for my supplementing—as I suspect different starch granules feed different bacterial strains differently. I notice increased satiety, although that could be because of the bone broth I am drinking as well now. I have maintained saltwater tanks without one, and while a fish ony tank is pretty easy so long as you deal with the ammonia and nitrites which is easy and automatic if you set it up properly and build the bioload slowly so the bacteria multiply commensurate with the bio load (including fish waste and unconsumed food), nitrates are a whole other story and require anaerobic bacteria because algae scrubbers won’t cut is and cause their own problems anyway from decay.
Lyxumia now likely won’t be available in the US until 2016 at the earliest, even though it has been approved in Europe since February 2013. ELIXA is expected to report results in 2015, meaning an FDA decision on Lyxumia will likely be delayed until at least 2016. Therefore, Sanofi would run the risk of invalidating the (very expensive) trial if it disclosed interim data now.
LixiLan’s FDA review is dependent on the approval of Lyxumia, so while Sanofi has not commented directly on LixiLan’s timeline, it is likely that the earliest it could receive approval in the US will now also be 2016. When blood sugar is high, GLP-1 agonists trigger the secretion of insulin, suppress the release of sugar from the liver, and slow the digestion of food. Sanofi is also working on combining lixisentatide and the basal insulin Lantus in a single device.
The once-weekly Bydureon injection gives individuals the freedom not to worry about a taking a daily drug. We’re excited by this development because if the combination is approved, Byetta could become an attractive (and reimbursable) option for many who do not want to take “mealtime insulin” to control post-meal glucose levels. Meanwhile, sanofi-aventis is finalizing plans for trials for its own candidate GLP-1 agonist lixisenatide with Lantus. One advantage is that GLP-1 agonists and basal insulins act in complementary ways to lower blood glucose, meaning that the use of both therapies together may well improve blood glucose control more effectively than either therapy alone.

The approval was based upon a study that looked at the safety and effectiveness of treating people with Levemir, a basal insulin, who were already using Victoza and metformin. Over 26 weeks, those receiving albiglutide achieved significantly greater reductions in A1c than those receiving Humalog (0.82% vs.
The device is currently under development, and Sanofi has indicated that trials will begin in early 2013. There is one human study saying that the risk of death from heart disease can be reduced by 43% in women and 19% in men on consuming 54 g of apple per day. No real difference in sleep so far, though my dose is probably too low and not close enough towards the evening.
In my part of the world, I have access to a product called FiberFine produced by a Norwegian company which also develops other interesting stuff (the Sukrin products for example, they also have a nice bread mix which contains a lot of RS).
A cardiovascular outcomes trial is required by the FDA to ensure that a drug doesn’t increase patients’ risk of heart disease.
This decision highlights the sizable challenges of conducting a long-term trial while pursuing regulatory approval of a new drug*.
For others, after-meal blood glucose spikes may be a greater problem, and lixisenatide might be a good choice.
We have also learned from conversations with healthcare providers that--although not approved by the FDA or other regulatory agencies, not promoted by companies, and not covered by many insurance companies--this combination is still quite commonly prescribed today. Over 52 weeks, those treated with Levemir achieved an additional A1c reduction of 0.5% over those who were not. If you are wondering what glycemic index is, let me tell you that it is the measure of how a food affects the rise in the levels of blood sugar on consumption.
When you see the data, compiled by a PhD Chemist, a very precious few of you might begin getting a clue that all starch is not created equal. I had already supplemented with potato starch in the past (and my wife was not too happy … fartage you know) but I found the taste rather unattractive, and this FiberFine is better in this respect (not the price though).
Apart from controlling blood sugar, the two major benefits of the drug are a low risk of hypoglycemia and weight loss, and the main side effect is nausea. The combination would certainly be less of a hassle for patients and may help improve glucose control much more than each therapy used alone.
More options are good news for patients, and the expansion of this drug class will make it easier for individuals to optimize their type 2 diabetes management. Moreover, basal insulins act slowly and over a long period of time to cover background insulin needs, while GLP-1 agonists stimulate insulin secretion only when blood glucose levels are high. The risk for hypoglycemia was higher among those receiving Levemir, although the risk was still low (0.228 episodes per patient year vs. I saw that it was based on the Hi-Maize stuff and I know that you guys are not really keen on it because of the marketing bollockery and price.
Sanofi, which will market Lyxumia, has announced that it will be available in Germany and the UK in the early months of 2013. Since patients typically lose weight while taking GLP-1 agonists, the combination could also overcome the weight gain usually seen with insulin therapy. This makes GLP-1 agonists effective therapies f0r post-meal glucose spikes without increasing the risk for hypoglycemia.
As expected, the most common side effects among those receiving albiglutide were nausea (13.0% with albiglutide vs.
Instead of allowing users to adjust their insulin dose separately from their GLP-1 dose, the drugs (Victoza and the company’s latest basal insulin called degludec) will always be injected together at a fixed ratio to one another. My FBS went down on the diet with more carbs, but I started slowly regaining weight,got some inflammation near a root of one of teeth, retained water, got less stable energy, so eventually I choose more important for me things over a number.
Unfortunately, Sanofi recently ran into a “technical glitch” that will delay its lixisenatide-Lantus “fix-flex” device from starting phase 3 trials in the first half of 2013. In other words, if a user reduces the amount of degludec they wish to inject, the amount of Victoza they will receive will be reduced as well. I do very green bananas as well almost every day (almost uneatable, dries the mouth instantly and blunts the sense of taste for a short while) and I like buckwheat (I make French crepes … since I am French myself ). Victoza’s approval for use alongside any basal insulin in the US follows the US approval of the GLP-1 agonist Byetta’s use with basal insulin Lantus last October (see new now next in diaTribe #37). Novo Nordisk has indicated that this approach will still allow over 80% of people to receive the right amount of basal insulin and enough Victoza to be effective in the body.
In comparison to Byetta, Victoza offers the convenience of fewer injections (once per day vs.
The use of albiglutide in combination with a basal insulin could reduce the number of required injections per week by 13 versus Byetta and six versus Victoza. Two phase two trials for this device are underway, which are expected to complete in the second half of this year. GlaxoSmithKline has not yet revealed when it might apply for approval for albiglutide as a therapy for type 2 diabetes, but we believe it will likely be in 2013, placing a possible approval in early 2014.
Assuming the trials complete as expected, approval may be possible as early as the end of 2013.
To date, no trials have compared the effectiveness of Victoza and Byetta when used with a basal insulin, although some scientists have argued that shorter acting GLP-1 agonists (like Byetta) may offer greater effectiveness because of their greater effects on post-meal glucose levels. Nonetheless, this approval for Victoza is certainly exciting, and we expect reimbursement and access to this treatment option to improve in the months ahead.

How much do glucose tablets raise blood sugar
Blood glucose monitor on nhs trust


  1. 02.04.2016 at 13:59:51

    With diabetes mellitus and and increase your risk of complications blood.

    Author: BAKI_FC
  2. 02.04.2016 at 15:43:29

    With intravenous glucose infusions hunger, faintness, weakness, and numbness.

    Author: FenerbahceX